As a milestone breakthrough of stem cell and regenerative medicine in recent years, somatic cell reprogramming has opened up new applications of regenerative medicine by breaking through the ethical shackles of embryonic stem cells. However, induced pluripotent stem (iPS) cells are prepared with a complicated protocol that results in a low reprogramming rate. To obtain differentiated target cells, iPS cells and embryonic stem cells still need to be induced using step-by-step procedures. The safety of induced target cells from iPS cells is currently a further concerning matter. More broadly conceived is lineage reprogramming that has been investigated since 1987. Adult stem cell plasticity, which triggered interest in stem cell research at the end of the last century, can also be included in the scope of lineage reprogramming. With the promotion of iPS cell research, lineage reprogramming is now considered as one of the most promising fields in regenerative medicine, will hopefully lead to customized, personalized therapeutic options for patients in the future.
The word "programme" stands for a list of instructions written in a programming language, which controls the behavior of a machine or computer. The programming language is known as a computer language for computers, while in cells, it is an epigenetic language in which programme means a series of normal developmental and differentiation processes arranged in an orderly manner. "Reprogramme" is the reversal of programming. It refers to erasure and remodeling of the functional state of the genome, resulting in conversion of a differentiated cell to an immature cell. Reprogramming can be divided into two types: pluripotent and lineage reprogramming. Of the two, the former includes nuclear transfer, cell fusion, iPS cell reprogramming and long-term in vitro cell culture [1] . The latter refers to directly converting specialized cells (or progenitor cells) from one lineage to another without conversion to the iPS cell stage, including transdifferentiation, dedifferentiation, transdetermination, and metaplasia [2] .
In the review of the history of reprogramming, we found that the development of lineage reprogramming occurred earlier than iPS cell establishment in 2006 [3] . In 1987, Davis et al. successfully reprogrammed fibroblasts to muscle cells by forced expression of the transcription factor MyoD [4] . In 2004, Xie et al. achieved reprogramming of B cells into macrophages by forced expression of the transcription factor C/EBPα [5] . In an interview after winning the Nobel Prize, Yamanaka said that he was inspired by the discovery of Davis in 1987 . Therefore, the studies of lineage reprogramming laid the foundation for the emergence of iPS cells. This article will systematically review the research progress of lineage reprogramming since 1999 when Petersen et al. reported a bone marrow source of hepatocytes [6] .
Transdifferentiation
Transdifferentiation refers to direct fate switching between two distinct cell types without passing through the pluripotency stage, which is also called lineage switching or lineage conversion [7] .
Studies of adult stem cell plasticity, including bone marrow-derived hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs), brought about worldwide enthusiasm for stem cells in biological and medical fields. As the first well studied and recognized stem cell types, HSCs had been the focus of most research concerning adult stem cell plasticity. In addition to hematopoietic reconstitution and a tri-lineage differentiation potential including osteoblasts, adipocytes and chondroblasts, many studies have demonstrated that HSCs and MSCs can be induced into various types of functional cells including hepatocytes, skeletal muscle cells, cardiac cells, endothelial cells, and neural cells [8, 9] .
During this time, most researchers hypothesized a mechanism of "transdifferentiation". It should be noted that the concept of "transdifferentiation", in which the cells are adult stem cells rather than differentiated cells, is different from transdifferentiation described in this review. Here, we categorize "transdifferentiation" into transdetermination that will be discussed in detail below.
Since 2006, transdifferentiation strategy-based cell conversions from one mature cell type to another target cell type have been achieved by forced expression of transcription factors essential for development of the lineage (Table   1 ). Such achievements have been extended from neural cells to other tissues including blood, heart, and liver. Fibroblasts have been used as starting cells in most of the studies, because of their accessibility. Several conclusions can be drawn from Table 1 : (i) In principle, transdifferentiation is easier between two closely related cell types than it is for more distantly related cell types. For example, only a single transcription factor (C/EBPα or C/EBPβ) is needed for cell conversion from B cells to macrophages [5] , whereas both PU.1 and C/EBPα are necessary for conversion of fibroblasts to macrophages [10] . (ii) Transdifferentiation is easier in mouse cells than that in human cells in terms of conversion efficiency and the required number of transcription factors. For example, only three transcription factors (Ascl1, Brn2, and Myt1l) are needed for cell conversion from fibroblasts to neural cells [13] , whereas the same conversion in human cells is unsuccessful without the addition of another transcription factor, namely NeuroD1 [14] , or one of Lmx1a and FoxA2 [15] .
Most of the starting cell types and associated final target cell types in transdifferentiation originate from the same germ layer summarized in Table 1 . Based on the same strategy, transdifferentiation has achieved conversion of fibroblasts to hepatocytes [18, 19] , and hepatocytes to neural cells [20] , which are the most clear transdifferentiation events that cross germ layers. These findings are advancing the success of regenerative medicine. 
Dedifferentiation
Dedifferentiation is the reversion of differentiated cells to a less differentiated state with loss of specialized cell functions and structures, which can be differentiated into other cell types. Induced conversion of somatic cells to pluripotent stem cells (i.e., iPS cells) can be considered as the most typical example. The majority of dedifferentiation-based strategies of lineage reprogramming are cell conversions of mature cells to unipotent or multipotent stem cells, which has been achieved with blood, cardiac and neural cells as well as melanocytes ( Table 2) . iPS reprogramming factors are mostly used to induce starting cells into an unstable intermediate population [25] that can be differentiated into target cells by external cues such as specific growth factors. The use and combinations of iPS reprogramming factors are not the same for distinct target cells. For example, forced expression of a single transcription factor, Oct-4, allows the generation of an intermediate population that gives rise to blood lineages [22] , whereas at least three factors including Oct-4, which is indispensable, are required for cell conversion to cardiac and neural cells [24, 25] . However, Their et al. [26] reported that constitutive induction of Sox2, Klf4, and c-Myc while strictly limiting Oct-4 activity to the initial phase of reprogramming allows the generation of stably expandable neural stem cells (NSCs). Because Sox2, Klf4, and c-Myc are endogenous transcription factors in NSCs, their expression is not limited during lineage reprogramming. Another study reported that transient induction of the four reprogramming factors (Oct-4, Sox2, Klf4, and c-Myc) could efficiently convert fibroblasts to functional neural stem/progenitor cells [25] . These observations indicate that exogenous expression of iPS cell reprogramming factors must be controlled for the production of stably expandable target cells.
Interestingly, adult hematopoietic programs are activated in CD45 + fibroblasts overexpressing Oct-4 [22] . Erythropoietin-treated CD45 + fibroblasts overexpressing Oct-4 generate erythroid cells expressing adult β-globin protein rather than embryonic ζ-globin [22] [23] . Although these two studies are not comparable because of distinct species, starting cells, and transcription factors, it can be concluded that such a route of dedifferentiation may not be the only one.
It is noteworthy that both transdifferentiation and dedifferentiation strategies enable the expansion and/or self-renewal of target cells [16, 18, 25, 26] . A typical example includes the work by Their et al. [26] . They generated neurosphere-like colonies that can be expanded for more than 50 passages, which may facilitate potential applications in regenerative medicine.
Transdetermination
Transdetermination refers to reprogramming of a committed but not yet fully differentiated cell type into another [7] . The adult stem cell plasticity of HSCs and MSCs can be catego- − populations with injured minced liver tissues, and coculture with normal liver tissues or culture alone were the controls. Our laboratory [29] previously isolated a subset of umbilical cord blood-derived β 2 m − cMet + cells that display some morphological characteristics of hepatocytes after indirect coculture with transgenic hepatic stellate cells. Several hepatocyte-specific genes are also expressed at mRNA and protein levels. In addition, the induced cells display liver-specific functions. These results suggest that a subset of umbilical cord blood cells can be transdeterminated into hepatocyte-like cells under indirect coculture conditions. We also showed that approximately 70% of the MSCs from human umbilical cord blood exhibit a typical neuron-like phenotype in vitro when provided with suitable external clues [30] .
In subsequent studies, researchers reported that cell fusion might be the principal mechanism of adult stem cell plasticity. Cell fusion is a cellular combination of donor blood cells with host cells to produce heterokaryons with a hybrid or mixed phenotype. Cell fusion has been confirmed in a liver transplantation model under normal and pathological conditions, which exhibits a frequency between 1/10 4 and 1/10 6 . Wang et al. [31] and Vassilopoulos et al. [32] first detected these hybrid cells in FAH -/-mice. It has been established that myelomonocytic cells are the major source of hepatocyte fusion partners. However, Tanabe et al. [33] detected hepatocyte-like cells with mouse and human chromosomes, and cells with only human chromosomes in receipt mice transplanted with human cord blood cells. These studies demonstrate that both cell fusion and transdetermination may be the mechanisms for human cord blood cell-derived hepatocyte-like cells in transplanted mouse models.
However, the limited knowledge of external cues in transdetermination hinders the clinical potential of regenerative medicine, resulting in the low frequency of emerging target cells after growth factor induction in vitro or transplantation into an animal model of injury in vivo. Therefore, we have performed genetic manipulation of adult stem cells by a transcription factor-based transdetermination strategy. For example, such an approach can promote neural differentiation of human bone marrow MSCs by overexpression of brain-derived neurotrophic factor [34] or knockdown of neuron-restrictive silencer factor (NRSF) [35] . Moreover, pancreatic differentiation is enhanced by overexpression of pancreatic and duodenal homeobox 1 in human bone marrow MSCs [36] or knockdown of NRSF in human amniotic fluid-derived stem cells [37] . Interestingly, the same genetic modification with one transcription factor (NRSF) will trigger distinct cell conversion in human bone marrow MSCs and human amniotic fluid-derived stem cells, suggesting that the developmental stage of starting cells is involved in determination of cell reprogramming.
Physiological and pathogenic cell conversions
Metaplasia refers to more general transformation of one tissue type into another, which is usually stimulated by chronic inflammation [7, 38] . It often involves the transformation of undifferentiated stem or progenitor cells into another cell type that is similar in nature. Common examples of metaplasia include squamous, intestinal and mesenchymal metaplasia.
Another common example of cell conversion is epithelial to mesenchymal transition (EMT). It is activated by the expression of important inducers of EMT, including transcription factors Snail, Slug and Twist in epithelial cells, resulting in changes of the cellular behavior. During the EMT process, the expression of E-cadherin and other epithelial cell markers is downregulated, while the expression of mesenchymal cell markers including N-cadherin, vimentin and α-smooth muscle actin is upregulated. The epithelial cells adopt a mesenchymal cell phenotype in appearance and acquire motility as well as invasive properties. A reversal of EMT process is mesenchymal-epithelial transition (i.e., MET). EMT-MET plasticity plays an important role in embryonic development, iPS cell reprogramming, and tumor progression [3941]. It is certain that new physiological and pathogenic cell conversions will be discovered with the development of lineage tracing technology. The differences between the several types of cell conversions mentioned above are listed in Figure 1 .
Application prospects of lineage reprogramming
Thus far, the strategy for lineage reprogramming has predominantly been forced expression of transcription factors. However, cell conversion from fibroblasts to neural cells has been reported by ectopic expression of microRNAs including miR-9/9* and miR-124 [42] , but at a low rate of conversion. This process is facilitated by NeuroD2 overexpression and the addition of neurogenic transcription factors Ascl1 and Myt1l. It is unknown whether the effects of interactions in the network of miRNA-target genes on reprogramming can be controlled or predicted.
In terms of application, the use of small molecules may be a good choice, which will facilitate the emergence of clinical applications. For example, during dedifferentiation, the addition of a JAK inhibitor can inhibit long-term expression of exogenous transcription factors including Oct-4, Sox2, Klf4 and c-Myc, which will block further dedifferentiation from an unstable intermediate to an iPS cell [24] . Small molecules have an enormous potential to facilitate the application of lineage reprogramming. Thus far, a growing number of small molecules have proved to be efficient and safe in reprogramming [43] . Perhaps several lineagereprogramming cocktails of small molecules suitable for different target cells will be developed in the near future. Genetic manipulation involves overexpression, knockdown [18] or knockout [21] strategies. In most studies, transfection of transcription factors uses viral vectors that have safety concerns, as is the case with iPS cells. Thus, it is of crucial importance to reprogramme fibroblasts to NSCs by transient overexpression of Oct-4, Sox2, Klf4 and c-Myc [25] , and mouse mesoderm to heart tissues by transient overexpression of Gata4, Tbx5, and Baf60c [11] . Transient expression of lineage reprogramming factors to achieve a full phenotypic switch is one of the most promising strategies in stem cell and regenerative medicine translational research.
A comparison of the lineage and iPS cell reprogramming strategies is listed in Table 3 . In Table 3 , limited cell scaling is in contrast to the near unlimited capacity for expansion of iPS/embryonic stem cells. In fact, lineage reprogramming-derived expandable NSCs and proliferating hepatocytes have been achieved recently [18, 25, 26] . In addition, in vivo regeneration has been described in a report by Zhou et al. [45] . Adenoviral vectors encoding a specific combination of three transcription factors, Ngn3, Pdx1 and Mafa, were delivered into the differentiated pancreatic exocrine cells of adult mice of which 2/3 were infected successfully after one month. About 20% of the infected cells were reprogrammed into insulin-secreting cells that closely resembled β-cells. Such an approach can be considered as in vivo lineage reprogramming and a new type of gene therapy. In terms of the tumor risk, it is low for lineage reprogramming without reversion to a pluripotent stem cell state. Notably, it is important to precisely control the time point when unstable intermediates in dedifferentiation strategy are emerging. Further research is still needed to elucidate new transcription factors, cell conversion strategies, and the underlying mechanisms of lineage reprogramming.
In summary, compared with studies of adult stem cell plasticity, lineage-reprogramming research has made great progress. Specifically, the cell conversion efficiency has been greatly increased, and reprogrammed cells can be expanded. These achievements establish the clinical foundation for lineage reprogramming in regenerative medicine.
In the near future, for a bedridden patient, it may be routine to take a skin sample to culture fibroblasts under standard conditions, and a reprogramming kit will be used to reprogramme the fibroblasts into expandable stem/progenitor cells that will be injected to regenerate the injured tissues of the patient. Perhaps this procedure will become routine work for a department of stem cell and regenerative medicine in a hospital. The customized and individualized clinical applications of reprogrammed stem/progenitor cells are the most attractive to researchers and patients in regenerative medicine.
